Clinical Effect of Tyrosine Kinase Inhibitors in the Treatment of P230 Chronic Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2021.06.010
- Author:
Ya-Qin JIANG
1
;
Na XU
2
;
Xiao-Li LIU
2
;
Ji-Shi WANG
3
;
Zhong YUAN
4
;
Ji-Xian HUANG
5
;
Jian-Yu WENG
6
;
Shu-Yun CAO
3
;
Shi-Shan XIAO
1
;
Hong-Qian ZHU
7
Author Information
1. Department of Hematology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China.
2. Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
3. Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, China.
4. Department of Hematology, The Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China.
5. Department of Hematology, Yuebei People's Hospital, Shaoguan 512025, Guangdong Province, China.
6. Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou 510080, Guangdong Province, China.
7. Department of Hematology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China E-mail: zhuhongqian@126.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Dasatinib;
Female;
Fusion Proteins, bcr-abl/genetics*;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Male;
Middle Aged;
Protein Kinase Inhibitors;
Young Adult
- From:
Journal of Experimental Hematology
2021;29(6):1752-1756
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the curative efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of e19a2 transcript (P230) CML chronic phase (CML-CP) patients.
METHODS:The clinical data of 11 P230 CML-CP patients were collected from July 2008 to December 2019. Blood routine examination, bone marrow cytology, chromosome, and BCR-ABL qualitative and quantitative tests were performed at initial diagnosis. After TKIs treatment, BCR-ABL (P230)/ABL in peripheral blood was regularly detected to evaluate molecular response by real-time quantitative PCR.
RESULTS:There were 11 patients (7 males and 4 females) in chronic phase from 6 domestic hospitals enrolled, their median age was 46 years old (range from 19 to 56 years old). Among 4 patients treated with imatinib (400 mg, qd) firstly, 3 cases switched to nilotinib (400 mg, bid) and 1 case switched to dasatinib (100 mg, qd) due to failure to achieve best molecular response at the landmark time or mutation of ABL kinase. Then major molecular response (MMR) was obtained within 1 year. In addition, 5 patients were treated with nilotinib (300 mg, bid) and 2 patients with dasatinib (100 mg, qd) as first-line treatment, all of them got MMR within 6 months.
CONCLUSION:For intolerance or resistance to imatinib, second-generation TKIs can enable P230 CML patients to achieve deeper molecular response, and MMR in a short time.
